Today's Top 5
5. Registry Study of Anticoagulation after COVID-19 Hospital Discharge
Registry #CORE19 study (N=4.9K) of #anticoagulation after #COVID19 hosp discharge
— Tatiana Prowell, MD (@tmprowell) April 7, 2021
👉Primary composite endpt (major thromboembolism + all cause mortality) occurred in 7.1%
👉13.2% got anticoag at dc
👉46% ⬇️ in events w/ anticoag, mostly prophylactic dosehttps://t.co/c7v67RmhhF
4. Adjuvant Immunotherapy in GU Cancers
Adjuvant immunotherapy on the roll in GU cancers: now it’s time for #RCC will we need OS data also here? Will the magnitude of DFS benefit change the practice? Any role of biomarkers? Lots to discuss #ASCO2021 @u_capitanio @DanieleRaggi83 https://t.co/KLEAKkoQXe
— Andrea Necchi (@AndreaNecchi) April 8, 2021
3. Twitter Use Among Hem/Onc Trainees
Patterns of Twitter use among trainees in hematology-oncology related areas - Miguel Gonzalez Velez @NarjustDumaMD @DanielCabrera @AMarshallMD @DrAttai @DrMarkham @Rfonsi1 J Clin Oncol 38: 2020 (suppl; abstr 11041) #ASCO20 https://t.co/gQgx39RtLv #socialoncology #MedEd #COSMO21 pic.twitter.com/chtJPssmMl
— Mike Thompson, MD, PhD, FASCO (@mtmdphd) April 8, 2021
2. Happening Now: AACR 2021 Annual Meeting
🚨⭐️It’s #AACR21 all ! Buckle up your seatbelts & enjoy the ride. Amazing science & terrific presentations ! Looking forward to present in the Clinical Trials Plenary Session on RET & Clinical Trails Mini-symposium on BRAF #PrecisionMedicine @AACR pic.twitter.com/FA2AiAPcuB
— Vivek Subbiah, MD (@VivekSubbiah) April 9, 2021
1. The Angiosarcoma Project
@corrie_painter discusses The Angiosarcoma Project - this revealed subtypes at genomic level + above clavicle indicates sun damage aetiology ➡️ sensitivity to checkpoint inhibitors
— Alice Maguire (@alicelmaguire) April 9, 2021
⬆️ Partnering with patients can rapidly increase understanding of disease 🤝🌟#COSMO21 #COSMOnc